SUNNYVALE, Calif., Jan. 11, 2011 /PRNewswire/ -- Accuray Incorporated  (Nasdaq: ARAY ), a global leader in the field of radiosurgery, announced today the first published five-year outcomes on low risk prostate cancer  patients treated with the CyberKnife® Robotic Radiosurgery System . The multi-center study, published in the January 10, 2011 issue of Radiation Oncology, found that 93 percent of patients had no recurrence of their cancer at a median follow-up of five years, a rate that compares favorably to results obtained with other treatment modalities, including surgery and conventional radiation therapy.
The study, "Stereotactic Body Radiotherapy for Low-Risk Prostate Cancer: Five-Year Outcomes,"  combined data from 41 patients treated at Stanford University in Stanford, Calif. and Naples Community Hospital in Naples, Fla. with a median follow-up of five years. The paper represents the longest published study to date on the use of CyberKnife radiosurgery, also referred to as stereotactic body radiotherapy (SBRT), as a treatment approach for clinically localized, low-risk prostate cancer. In addition to demonstrating high five-year disease-free survival rates, the study also found generally low levels of urinary and rectal toxicity following the five-day course of treatment, concluding that CyberKnife radiosurgery can achieve high rates of disease control while sparing critical structures, thereby minimizing undesirable side effects typically associated with prostate cancer treatments and preserving patients' quality of life.
"As a non-invasive treatment option completed in just five visits, stereotactic radiotherapy with the CyberKnife System offers pati